Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter ended June 30, 2004 (First Quarter of Fiscal Year 2005)
Business Overview: McKesson is a leading healthcare services company operating through three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Provider Technologies. The company reorganized its reporting segments effective April 1, 2004.
Key Financial Metrics
| Metric | Q1 2005 (Jun 30, 2004) | Q1 2004 (Jun 30, 2003) |
|---|---|---|
| Revenues | $19,186.6 million | $16,524.2 million |
| Gross Profit | $852.0 million | $786.5 million |
| Operating Income | $260.8 million | $251.6 million |
| Net Income | $163.6 million | $155.6 million |
| Diluted EPS | $0.55 | $0.53 |
| Cash from Operations | $128.3 million | $40.8 million |
| Cash & Equivalents (End of Period) | $836.7 million | $445.2 million |
| Total Debt (Short-term + Long-term) | $1,491.6 million | Not explicitly aggregated in text |
| Working Capital | $3,803.9 million | Not explicitly stated for prior period |
Margins: Gross profit margin was 4.44% (down 32 basis points from 4.76%). Operating expense ratio was 3.08% (down 16 basis points from 3.24%).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 16% year-over-year, driven primarily by the Pharmaceutical Solutions segment (17% growth), which accounts for over 94% of total revenue. Growth was fueled by market expansion, new institutional customers (including a new Department of Veterans Affairs contract), and Canadian operations.
- Profitability: Net income rose 5% to $163.6 million. Segment operating profits increased across all three divisions, with Provider Technologies seeing a 204% increase in operating profit due to expense control and revenue growth.
- Margin Pressure: Consolidated gross margins declined 32 basis points. The Pharmaceutical Solutions segment faced lower selling margins due to competitive pricing pressure and a shift in customer mix toward institutional clients with lower margins, partially offset by higher generic drug sales and a $41.2 million antitrust settlement credit.
- Corporate Expenses: Corporate expenses surged 87% to $64.9 million (from $34.7 million). This increase was primarily due to a $12 million pension settlement charge and higher legal costs related to pending securities litigation. The prior year benefited from an $8.5 million gain on the sale of surplus property.
- Acquisitions: The company acquired Moore Medical Corp. (MMC) for approximately $37 million in cash on April 1, 2004, integrating it into the Medical-Surgical Solutions segment.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects the Department of Veterans Affairs contract to generate annual revenues exceeding $3.5 billion. The Medical-Surgical segment anticipates completing an evaluation of its distribution center network in the second quarter of 2005 following the MMC acquisition.
- Unusual Items:
- Antitrust Settlement: Received $41.2 million in cash proceeds from an antitrust class action lawsuit settlement, recorded as a credit to cost of sales.
- Pension Settlement: Made $42 million in lump-sum payments from an unfunded U.S. pension plan, resulting in a $12 million settlement charge expensed in the quarter.
- Divestiture Loss: Sold a business for net cash proceeds of $12.3 million, resulting in a pre-tax loss of $1.1 million and an after-tax loss of $4.6 million.
- Risks and Contingencies:
- Accounting Litigation: Ongoing shareholder litigation regarding the 1999 restatement of financial statements. The company cannot predict the outcome or potential loss range, which could be material.
- NHS Contract: A $500 million, 10-year contract with the UK's National Health Services (NHS) has faced delays, increasing costs and reducing revenue recognition time. The company has invested approximately $78 million in net assets. Failure to agree on an updated implementation plan could result in material losses or asset impairment.
- Employment Litigation: A judgment was entered against the company in a wrongful termination case totaling $18.5 million ($2.8 million compensatory, $15.0 million punitive). The company is appealing.
Investor Verification Checklist
- NHS Contract Status: Verify the outcome of negotiations with the UK NHS regarding the $500 million contract and the potential for asset impairment of the $78 million invested.
- Legal Exposure: Monitor developments in the "Accounting Litigation" and the appeal of the $18.5 million employment judgment for potential material financial impact.
- Margin Trends: Assess whether the decline in Pharmaceutical Solutions gross margins is a temporary anomaly or a structural shift due to industry pricing pressures and customer mix changes.
- Working Capital Efficiency: Review the impact of the new Veterans Affairs contract (prompt payment terms) on future cash flow and working capital requirements.
- Debt Covenants: Confirm continued compliance with the debt-to-capital ratio covenant (currently 21.6% vs. 56.5% limit) given the increase in corporate expenses and pension charges.